Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Macbecin SCHEMBL2682391 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL2682389 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL12800037 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL2682385 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL2682394 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL13040915 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL13040899 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL25344099 | 0.95 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL29420374 | 0.95 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL21578242 | 0.95 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758526-B2 | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH (US) | 2020-09-01 | — | — | US | disclosed |
| US-20170095575-A1 | COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| EP-2914259-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150150850-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150099721-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2849751-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8906885-B2 | Treating cancer with HSP90 inhibitory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140294808-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2729144-A2 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20140127740-A1 | METHODS OF IDENTIFYING HSP90 INHIBITORS WITH LESS OCULAR TOXICITY | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-08 | — | — | US | disclosed |
| WO-2014063080-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-8628752-B2 | Methods of identifying HSP90 inhibitors with less ocular toxicity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2014-01-14 | — | — | US | disclosed |
| WO-2013170159-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2616063-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | Synta Pharmaceuticals Corp. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130109045-A1 | METHODS OF IDENTIFYING HSP90 INHIBITORS WITH LESS OCULAR TOXICITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2013006864-A2 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012037072-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885ALDH1A1 2361/4885ERBB2 933/4885 |
| US-20150099721-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | ROS1, RET, HSP90AB1 | HSP90AA1 4/4885ALDH1A1 733/4885ERBB2 64/4885 |
| US-10758526-B2 | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways | IGLV6-57, IGSF11, TNFRSF9 | HSP90AA1 1604/4885ALDH1A1 2310/4885ERBB2 545/4885 |
| US-20170095575-A1 | COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS | IGLV6-57, IGSF11, TNFRSF9 | HSP90AA1 1604/4885ALDH1A1 2310/4885ERBB2 545/4885 |
| US-20150150850-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | HSP90AB1, MET, HSP90AA1 | HSP90AA1 3/4885ALDH1A1 289/4885ERBB2 32/4885 |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885ALDH1A1 2934/4885ERBB2 20/4885 |
| US-20140294808-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | HSP90AB1, MET, HSP90AA1 | HSP90AA1 3/4885ALDH1A1 285/4885ERBB2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.